Physician profile
Prasant Pandey
NPI 1457466518
$14,670.00
in general payments reported to CMS, 2019-2025
30 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,877 · 2020: $384 · 2021: $2,128 · 2022: $1,016 · 2023: $1,797 · 2024: $1,344 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,747.95 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,413.90 | 2019-2024 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $918.40 | 2020-2025 | Lokelma, Brilinta, Farxiga |
| Medtronic, INC. | $766.35 | 2021-2024 | Venaseal, Corevalve Evolut R |
| Boston Scientific Corporation | $749.33 | 2019-2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $735.58 | 2020-2023 | Nexletol |
| Amgen INC. | $510.59 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $504.35 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $389.13 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abiomed | $349.50 | 2023-2025 | Impella |
| Pfizer INC. | $227.07 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.92 | 2021-2023 | |
| Scpharmaceuticals INC. | $151.81 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $140.90 | 2022-2023 | Arcalyst |
| Shire North American Group INC | $124.80 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $117.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $111.78 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Edwards Lifesciences Corporation | $108.27 | 2021 | |
| Endologix LLC | $106.53 | 2025 | Alto Abdominal Stent Graft System |
| Medtronic Vascular, INC. | $57.26 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $43.84 | 2022 | |
| Abbvie INC. | $41.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.50 | 2022-2023 | |
| Lilly USA, LLC | $27.51 | 2020 | |
| Amarin Pharma, INC. | $27.19 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $24.58 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.79 | 2022 | |
| Bard Peripheral Vascular, INC. | $20.72 | 2023 | Venclose Maven Catheter |
| Lantheus Medical Imaging, INC. | $19.52 | 2023 | Definity |
| Kowa Pharmaceuticals America, INC. | $18.40 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasant Pandey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.